national patent development corp and bar ilan university israel said joint venture corporation scientific testing inc will clinical trial its immuno augmenting compound as101 for treatment acquired immune deficiency syndrome aids study will conducted institute immunological disorders anderson hospital houston tex under direction peter mensell pursuant investigational new drug application filed with food and drug administration company said study expected four six weeks designed test effects as101 about aids patients national patent said added as101 proprietary synthetic compound invented bar ilan university doctors has immuno augmenting anti viral and anti tumor activity preclinical animal testing and immuno augmenting activity limited number aids patients phase foreign clinical tests reuter 